Sign In
Buy CHRS
$1.46
-0.0200 (-1.35%)
At Close: Jun 23, 2026
Coherus BioSciences: Current Weakness Represents A Buying Opportunity
02:12pm, Thursday, 19'th Mar 2020
Udenyca managed to surpass 20% market share by end of December 2019. The company has several promising biosimilar assets in pipeline. Investors should consider
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
12:00am, Thursday, 19'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
Pictet Asset Management Ltd. Invests $2.02 Million in Coherus Biosciences Inc (NASDAQ:CHRS)
08:56am, Tuesday, 17'th Mar 2020
Pictet Asset Management Ltd. bought a new position in shares of Coherus Biosciences Inc (NASDAQ:CHRS) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange C
Edited Transcript of CHRS earnings conference call or presentation 27-Feb-20 9:30pm GMT
06:43am, Saturday, 14'th Mar 2020
Q4 2019 Coherus BioSciences Inc Earnings Call
Mizuho Securities Sticks to Their Buy Rating for Unity Biotechnology (UBX)
05:05pm, Thursday, 12'th Mar 2020
Mizuho Securities analyst Salim Syed maintained a Buy rating on Unity Biotechnology (UBX) today and set a price target of $33.00. The company's shares
Mizuho Securities Sticks to Their Buy Rating for Unity Biotechnology (UBX)
05:05pm, Thursday, 12'th Mar 2020
Mizuho Securities analyst Salim Syed maintained a Buy rating on Unity Biotechnology (UBX – Research Report) today and set a
Bank of Montreal Can Grows Position in Coherus Biosciences Inc (NASDAQ:CHRS)
08:44am, Tuesday, 10'th Mar 2020
Bank of Montreal Can lifted its stake in Coherus Biosciences Inc (NASDAQ:CHRS) by 2,390.2% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owne
Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities
09:01am, Monday, 09'th Mar 2020
Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities
Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities
09:01am, Monday, 09'th Mar 2020
Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities
Charles Schwab Investment Management Inc. Raises Stake in Coherus Biosciences Inc (NASDAQ:CHRS)
08:12am, Sunday, 08'th Mar 2020
Charles Schwab Investment Management Inc. lifted its stake in shares of Coherus Biosciences Inc (NASDAQ:CHRS) by 75.1% during the fourth quarter, according to the company in its most recent filing wit
Contrasting Agenus (NASDAQ:AGEN) & Coherus Biosciences (NASDAQ:CHRS)
06:22am, Sunday, 08'th Mar 2020
Coherus Biosciences (NASDAQ:CHRS) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their ea
Trevena's NDA for Pain Drug Oliceridine Gets FDA Acceptance
09:47pm, Friday, 06'th Mar 2020
FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.
5 Stocks Trading Near 52-Week High That Can Scale Higher
01:48pm, Friday, 06'th Mar 2020
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
